
Physician scientist, hematology/oncology @tmhemonc.bsky.social
Fukuoka, Japan
Joined November 2012
- Tweets452
- Following413
- Followers399
- Likes343
I’ve decided to move to Bluesky. You can find me here: @tmhemonc.bsky.social. See you there!”
1
234
Takahiro Maeda retweeted
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation fda.gov/drugs/resources-info…
Takahiro Maeda retweeted
Couldn't have made a better choice! Congrats Ivan!
We're excited to welcome Dr. Ivan Maillard, the new Head of the Division of Hematologic Malignancies within the @MSK_DeptOfMed at MSK.
Learn more about Dr. Maillard and his new role: bit.ly/4epXj3O
Exciting news about the Pokemon degrader !(ash.confex.com/ash/2024/webp…)—Phase 1/2a trial is underway !!(NCT06481306)
1
6
647
Of note, while high p-STAT5 levels indicate JAK-STAT activation, this does not necessarily mean that the JAK-STAT axis is crucial for the fitness of CRLF2-r ALL cells. Our CRISPR functional screens have shown that STAT5 and STAT3 are dispensable in CRLF2-r ALL cells. 1/n
Constitutive STAT5 activation in precursor B-cell acute lymphoblastic leukemia with P2RY8::CRLF2 fusion
ow.ly/yBuu50TJ9ot #BloodWork #lymphoidneoplasia
1
4
600
Additionally, Ruxolitinib reduces p-STAT5 but fails to shut down the RAS and mTOR pathways, which are essential for cell survival (ashpublications.org/blood/ar…). We should await the results of trials like NCT02723994 regarding Ruxolitinib’s efficacy in CRLF2-r ALL. 2/2
199
造血器腫瘍分野の基礎研究でおすすめの学会です(2年に1度)。ボストン郊外に5日間ほどこの分野のtop scientistsと缶詰になるので、否が応でも交流が広がります。人脈を拡げる絶好の機会です。ボストンのベストシーズンでもあります。毎回日本人のプレゼンスがないので是非!events.faseb.org/event/hemat…
Takahiro Maeda retweeted
Sergei and I are excited to continue the tradition of exceptional scientific and career development sessions at the 2025 FASEB Meeting! There will also be lots of time for informal discussions, networking, and collaboration, making this a great meeting for trainees!!
Save the date for 2025 @FASEBorg Hematologic Malignancies Conference!! With @juliamaxson, we have a fantastic program with Keynotes by @TrowbridgeLab & @VassiliouLab. Look forward to welcoming everyone at the Wellsworth Hotel in MA! Updates soon #HEMSRC shorturl.at/1KWY6
Takahiro Maeda retweeted
There has been confusion over mitochondrial mutation detection, consensus variant calling, and lineage tracing in single cells. Here, we detail how ReDeeM addresses these challenges, improving detection of mtDNA mutations by 10-fold and lineage tracing. Led by @chenweng1991 and @JswLab, we now constructively address concerns raised: biorxiv.org/content/10.1101/…
Stay tuned for 🧵 from Chen.
#genomics #mitochondria #singlecell
日本血液学会/日本臨床腫瘍学会共催
白血病ゲノム医療教育事業オンラインセミナー
「AML診療におけるMRDの意義」
締切間近です。みなさんRTお願いします。
申し込みはこちらから:entry.convention.co.jp/f-sys…
Takahiro Maeda retweeted
大塚製薬の遺伝子パネル検査「ヘムサイト解析プログラム」承認へ 薬審・プログラム医療機器調査会が了承 mixonline.jp:443/Default.asp…
Takahiro Maeda retweeted
Genome-wide CRISPR/Cas9 screens identify the mTORC1 pathway as crucial for B-ALL cell sensitivity to dexamethasone. ow.ly/324650SMLLq #lymphoidneoplasia #acutelymphocyticleukemia #basicmechanismsofneoplasia
Takahiro Maeda retweeted
Estimating the probability of disease for people carrying a genetic variant - known as penetrance - is empowered by large population cohorts, but *very* easy to screw up. So @carolinefwright and friends (including me) explain how to do it right.
This Post is from an account that no longer exists. Learn more
Congrats Justin and team! Yes just in time:-) !
Wow, out just in time for your weekend reading-- our last four years labor of love "Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition"!! nature.com/articles/s41375-0… Congratulations to first author newly minted Dr. Sana Chaudhry! @SylvesterCancer 🧵
1
1
668
Our paper on the biomarker of selinexor (XPO1 inhibitor, FDA approved for R/R MM and DLBCL) sensitivity has been published online in Leukemia (rdcu.be/dNofH). Via CRISPR dropout screens, we found that DDX19 homologue dosage is key for selinexor sensitivity.
Next questions are:
• Is there a DDX19B-low T-ALL subset among human T-ALL cases?
• Is DDX19 a new drug target for hematological malignancies?
1
283


















